Suppression of breast cancer cell growth by Na(+)/H(+ )exchanger regulatory factor 1 (NHERF1) by Pan, Yong et al.
Open Access
Available online http://breast-cancer-research.com/content/8/6/R63
Page 1 of 10
(page number not for citation purposes)
Vol 8 No 6 Research article
Suppression of breast cancer cell growth by Na+/H+ exchanger 
regulatory factor 1 (NHERF1)
Yong Pan, Lei Wang and Jia Le Dai
Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, USA
Corresponding author: Jia Le Dai, jldai@mdanderson.org
Received: 17 Jul 2006 Revisions requested: 21 Aug 2006 Revisions received: 4 Sep 2006 Accepted: 1 Nov 2006 Published: 1 Nov 2006
Breast Cancer Research 2006, 8:R63 (doi:10.1186/bcr1616)
This article is online at: http://breast-cancer-research.com/content/8/6/R63
© 2006 Pan et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Na+/H+ exchanger regulatory factor 1 (NHERF1,
also known as EBP50  or  NHERF) is a putative tumour
suppressor gene in human breast cancer. Located at 17q25.1,
NHERF1 is frequently targeted during breast tumourigenesis.
Loss of heterozygosity (LOH) at the NHERF1 locus is found in
more than 50% of breast tumours. In addition, NHERF1  is
mutated in a subset of primary breast tumours and breast cancer
cell lines. LOH at the NHERF1 locus is strongly associated with
aggressive features of breast tumours, implicating NHERF1 as
a haploinsufficiency tumour suppressor gene. However, the
putative NHERF1 tumour suppressor activity has not been
functionally verified.
Methods To confirm the NHERF1 tumour suppressor activity
suggested by our genetic analyses, we used retrovirus-
transduced short hairpin RNA (shRNA) to knock down NHERF1
expression in breast cancer cell lines MCF7 and T47D. These
cells were then assessed for cell growth in vitro and in vivo. The
control and NHERF1 knockdown cells were also serum-starved
and re-fed to compare their cell cycle progression as measured
by fluorescence-activated cell sorting analyses.
Results We found that downregulation of the endogenous
NHERF1 in T47D or MCF7 cells resulted in enhanced cell
proliferation in both anchorage-dependent and -independent
conditions compared with that of the vector control cells.
NHERF1 knockdown T47D cells implanted at mammary fat
pads of athymic mice formed larger tumours than did control
cells. We found that serum-starved NHERF1 knockdown cells
had a faster G1-to-S transition after serum re-stimulation than
the control cells. Immunoblotting showed that the accelerated
cell cycle progression in NHERF1 knockdown cells was
accompanied by increased expression of cyclin E and elevated
Rb phosphorylation level.
Conclusion Our findings suggested that the normal NHERF1
function in mammary epithelial cells involves blockage of cell
cycle progression. Our study affirmed the tumour suppressor
activity of NHERF1 in breast which may be related to its
regulatory effect on cell cycle. It warrants future investigation of
this novel tumour suppressor pathway in human breast cancer
which may turn up therapeutic opportunities.
Introduction
Na+/H+ exchanger regulatory factor 1 (NHERF1, also known
as  EBP-50  or  NHERF) is a candidate tumour suppressor
gene in human breast cancer [1]. We reported loss of hetero-
zygosity (LOH) at the NHERF1 gene locus (17q25.1) in more
than 50% of human breast tumours. Such loss is infrequent,
however, in other tumour types, suggesting that NHERF1 is
specifically targeted during mammary tumourigenesis. In a
panel of breast tumours pre-screened for LOH, three intra-
genic mutations of NHERF1 were found (approximately 3%)
[1]. LOH at the NHERF1 locus is positively correlated with
aggressive features of breast tumours, including tumour size,
grade, and stage. The association indicates a critical role for
NHERF1 in mammary carcinogenesis, in which its putative
suppressor activity is haploinsufficient. The haploinsufficiency
of the NHERF1 gene may explain its relatively low frequency
of intragenic mutations.
ER = oestrogen receptor; ERE = oestrogen response element; ERM = ezrin-radixin-moesin; FACS = fluorescence-activated cell sorting; FBS = foetal 
bovine serum; LOH = loss of heterozygosity; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NF2 = neurofibromatosis-2; NHE3 
= Na+/H+ exchanger isoform 3; NHERF1 = Na+/H+ exchanger regulatory factor 1; PBS = phosphate-buffered saline; PDGFR = platelet-derived 
growth factor receptor; PDZ = PSD-95/Dlg/ZO1; PTEN = phosphatase and tensin homologue (mutated in multiple advanced cancers 1); shRNA = 
short hairpin RNA; SYK = spleen tyrosine kinase.Breast Cancer Research    Vol 8 No 6    Pan et al.
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The NHERF1 gene encodes an intracellular molecule that was
initially found to be a cofactor necessary for cAMP-mediated
inhibition of renal apical Na+/H+ exchanger isoform 3 (NHE3)
[2]. Human NHERF1 is a 358-amino acid protein that shares
high homologue at the modular structures with NHERF2 (also
known as E3KARP or TKA1) [3]. Both contain two tandem
PDZ (PSD-95/Dlg/ZO1) domains (PDZ-I and PDZ-II) at the
amino-terminus and an ezrin-radixin-moesin (ERM)-interacting
domain at the carboxyl-terminus. NHERF1 and NHERF2 are
highly expressed in polarised epithelial cells and are differen-
tially expressed in mammalian tissues [2]. NHERF1, the one
more extensively studied, acts as an important regulator and
integrator of multiple signaling pathways by virtue of its ability
to bind to a variety of proteins through its PDZ domains and an
ERM-interacting domain. Via its PDZ domains, NHERF1 spe-
cifically recognises carboxyl-terminal motif (S/T)XL, which is
present in a number of transmembrane proteins other than
NHE3, including cystic fibrosis transmembrane conductance
regulator [4-6], β2-adrenergic receptor [7,8], platelet-derived
growth factor receptor (PDGFR) [9,10], and sodium bicarbo-
nate co-transporter [11]. NHERF1 has also been shown to
interact with a variety of intracellular proteins, including phos-
pholipase C-β isoforms [12,13], GRK6A (G protein-coupled
receptor kinase 6A) [14], spleen tyrosine kinase (SYK) [1],
YAP65 (Yes-associated protein 65-kDa) [15], and β-catenin
[16]. The proteins recognised by PDZ-I do not, however, bind
to PDZ-II, and vice versa, indicating that the two PDZ domains
have distinct binding motifs [4,14].
NHERF1 binds, via its ERM-binding domain, to ERM proteins,
a family of actin cytoskeletal adaptor proteins [17,18]. One
ERM family member is merlin, the product of neurofibromato-
sis-2 (NF2), a tumour suppressor gene implicated in predispo-
sition to meningiomas and schwanomas [19,20]. The amino-
terminus of the ERM family proteins (ERM domain) interacts
with the ERM-binding domain of NHERF1 [17,18]. The inter-
action may be important for NHERF1 functions by connecting
membrane transporters and actin cytoskeleton [21,22]. Like
other ERM members, merlin interacts with NHERF1 through
its amino-terminus ERM domain. Notably, more than 80% of
NF2 mutations are located in this ERM domain [23], and the
mutant merlin proteins display significantly lower binding affin-
ity to NHERF1, suggesting that NHERF1 is related to merlin's
suppressor activity.
Among the multiple biologic pathways in which NHERF1 is
involved, the signaling event that is most relevant to NHERF1
pathobiology in mammary gland is not known, nor is it certain
that NHERF1 elicits tumour suppressor activity in breast.
Human NHERF1 was earlier shown to be an oestrogen-induc-
ible gene [24,25]. Based on a critical role of oestrogen in
mammary development and the early-stage progression of
breast cancer, NHERF1 was initially postulated as a mitogenic
factor [22], which is not supported by our genetic evidence
[1]. To clarify these contrasting views, we sought to determine
whether the proliferation of breast cancer cells is affected by
knockdown of NHERF1 expression.
Materials and methods
Cell culture
Human breast tumour cell lines BT20, BT474, BT483, BT549,
CAMA1, DU4475, HCC1428, HCC1954, MB157, MCF7,
MDA-MB-134, MDA-MB-231, MDA-MB-330, MDA-MB-361,
MDA-MB-415, MDA-MB-435S, MDA-MB-453, MDA-MB-
468, SKBr3, T47D, and ZR75-1 were purchased from Ameri-
can Type Culture Collection (Manassas, VA, USA). The
SUM149-PT line was a gift from Dr. Stephan Ethier (University
of Michigan, Ann Arbor, MI, USA). All cell lines were cultured
in recommended media supplemented with 10% foetal bovine
serum (FBS) (Invitrogen, Carlsbad, CA, USA).
Knockdown of NHERF1 expression
A vector-based short hairpin RNA (shRNA) method was used
to generate MCF7 and T47D cells with inhibited NHERF1
expression. A two-step ligation method [26] was used to insert
the interfering sequences into pBS/U6 (a gift from Dr. Yang
Shi, Harvard Medical School, Boston, MA, USA). Two
NHERF1 mRNA sequences corresponding to cDNA positions
786 and 910 were targeted. Oligonucleotide sequences for
NHERF-786 were 5'-GGAGATACAGAAGGAGAACAGA-3'
(oligo 1, forward), 5'-AGCTTCTGTTCTCCTTCTGTATCTCC-
3' (oligo 1, reverse), 5'-AGCTTCTGTTCTCCTTCTG-
TATCTCCCTTTTTG-3' (oligo 2, forward), and 5'-AAT-
TCAAAAAGGGAGATACAGAAGGAGAACAGA-3' (oligo 2,
reverse). Oligonucleotide sequences for NHERF-910 were 5'-
GGAAACTGACGAGTTCTTCAA-3' (oligo 1, forward), 5'-
AGCTTTGAAGAACTCGTCAGTTTCC-3' (oligo 1, reverse),
5'-AGCTTTGAAGAACTCGTCAGTTTCCCTTTTTG-3' (oligo
2, forward), and 5'-AATTCAAAAAGGGAAACTGACGAGT-
TCTTCAA-3' (oligo 2, reverse). Interference sequences were
verified by automated DNA sequencing. The hairpin loop
sequences were then released by digesting with BamHI and
EcoRI and subcloned into a retroviral vector pBabe-U6 (a gift
from Dr. Jinsong Liu, M. D. Anderson Cancer Center, Houston,
TX, USA) [27], yielding pBabe-U6/NHERF-786 and pBabe-
U6/NHERF-910. Retroviruses were produced by transfecting
packaging cells (amphotropic Phoenix) with pBabe-U6/
NHERF-786, pBabe-U6/NHERF-910, or parental pBabe-U6,
using Fugene 6 (Roche Applied Science, Indianapolis, IN,
USA). The medium was collected 2 days after transfection.
After centrifugation, the supernatant was then passed through
a 0.45-μm filter. The retrovirus stock was stored at -80°C until
use. Cultured MCF7 and T47D cells were infected with a virus
cocktail (1 ml of retroviral stock, 2 ml of medium, and 4 μg of
polybrene). The next day, the virus was removed and replaced
with fresh medium that contained 0.5 μg/ml puromycin. Surviv-
ing cells were assessed for NHERF1 expression by immunob-
lotting.Available online http://breast-cancer-research.com/content/8/6/R63
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Cell growth assay
Thymidine incorporation assay was used to measure the DNA
synthesis rate as described previously [26]. MCF7 and T47D
cells cultured in 24-well plates were pulsed with 1 mCi [3H]-
thymidine (3,000 Ci/mmol; PerkinElmer Life and Analytical
Sciences, Inc., Shelton, CT, USA). After 5-hour labeling, non-
incorporated tritium was removed by trichloroacetic acid
washes. Acid-insoluble tritium was assessed by scintillation
counting (microBeta Trilux 1450; Wallac, now PerkinElmer
Life and Analytical Sciences, Inc.). The relative cell prolifera-
tion rate was obtained by dividing the counts from cells in
which NHERF1 was downregulated by the ones from control
cells. Experiments were repeated three times.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assays were conducted to measure the relative number
of viable cells. Cells were seeded in 96-well cluster dishes at
2,500 cells per well with 100 μl of complete medium. At indi-
cated time points, medium was replaced with 100 μl of fresh
medium supplemented with 20 μl of 5 mg/ml MTT (Sigma-
Aldrich, St. Louis, MO, USA). The incubation lasted for 2 hours
before the medium was removed and cells dissolved in 100 μl
of lysis buffer. Absorbance was measured using a multiSkan
plate reader (Thermo Scientific, Waltham, MA, USA) at a
wavelength of 570 nm. Experiments were repeated at least
three times.
Anchorage-independent growth
Cells (1 × 104) were suspended in 1 ml of 1× culture medium
that contained 0.35% agarose. The suspension was added on
top of 4 ml of solidified 0.7% agarose. After the cells were set
in agarose, 1 ml of fresh medium was added to cover the aga-
rose. Assays were performed in triplicate. Plated cells were
incubated for 20 days at 37°C before formed colonies larger
than 50 μm in diameter were counted. Experiments were
repeated three times.
Assessment of cell cycle distribution
Cultured cells (approximately 2 × 106) were trypsinised and
washed twice with 1× phosphate-buffered saline (PBS). Cells
were then fixed by being added drop-wise to 5 ml of ice-cold
80% ethanol while vortexing. After fixing for at least 1 hour at
room temperature, the cells were stored at -20°C. Before
being stained, the cells were washed with 1× PBS and incu-
bated at 37°C for 30 minutes with propidium iodide (50 μg/ml;
Sigma-Aldrich) in the presence of 10 μl of RNase A (10 mg/
ml; Sigma-Aldrich). Cell cycle analysis was performed with an
FACS station equipped with CellQuest (Becton Dickinson,
Franklin Lakes, NJ, USA). At each cell cycle phase, the popu-
lation was determined by computer model fitting (Verity Soft-
ware House, Topsham, ME, USA).
Serum starvation was used to synchronise MCF7 at the G0/G1
phase. MCF7 cells were seeded at 8 × 105 per 60-mm dish.
After being cultured in complete medium overnight, cells were
incubated with serum-free medium for 1 day. The cells were
then re-fed with medium supplemented with 10% FBS for var-
ious time periods before being harvested for fluorescence-
activated cell sorting (FACS) analyses.
Experimental tumourigenicity assay
Four- to five-week-old female athymic nude mice (Harlan, Indi-
anapolis, IN, USA) were used for experimental tumourigenicity
assays. To facilitate the establishment of xenografts of oestro-
gen-dependent cells, each mouse was inoculated subcutane-
ously with an oestrogen pellet (0.7 mg 17β-estradiol per
pellet; 60-day slow-release; Innovative Research of America,
Sarasota, FL, USA). Two days after pellet implantation, equiv-
alent amounts of T47D cells (1.5 × 106; Babe control or
NHERF-910) resuspended in 100 μl of mixture (1:1 with un-
supplemented media) of Matrigel (BD Biosciences, San Jose,
CA, USA) were injected into each side of second-pair breast
mammary fat pads (3 × 106 cells in total). Six weeks after injec-
tion, mice were euthanised by carbon dioxide, and the estab-
lished tumours on both sides of mammary glands were
dissected, pooled, and weighed. All procedures were per-
formed according to the recommendations of the Institutional
Animal Care and Use Committee.
Immunoblotting
Immunoblottings were carried out essentially as described
previously [28]. Antibodies u s e d  w e r e  N H E R F 1  ( E X B I O
Praha, Bestec, Czech Republic), Rb and p27 (BD Bio-
sciences), cdk2 (Calbiochem, San Diego, CA, USA), cdk4
and cyclin D1 (Cell Signaling Technology, Inc., Danvers, MA,
USA), cyclin E and β-actin (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA), and α-tubulin (Sigma-Aldrich).
Results
NHERF1 expression in breast cancer cells
We used immunoblotting to analyse the expression of
NHERF1 in 22 breast cancer cell lines (Figure 1a), among
which the origin of MDA-MB-435S was under debate [29-31].
MDA-MB-231 and SUM149-PT, two lines harbouring both
NHERF1 mutation and LOH [1], had low NHERF1 protein lev-
els. High expression of NHERF1 was found in some oestrogen
receptor (ER)-α-positive cells, such as T47D, Zr75.1, and
MCF7, consistent with an earlier report that correlated
NHERF1 expression with ER-α positivity [32]. However,
NHERF1 expression does not necessarily follow the ER-α sta-
tus. For example, BT20 cells expressing constitutively active
ER-α had low NHERF1 expression, whereas NHERF1 was
maintained at a high level in ER-α-negative MDA-MB-453,
MDA-MB-468, and SKBr3 cells, suggesting that mechanisms
other than oestrogen induction must exert an effect on
NHERF1 expression.Breast Cancer Research    Vol 8 No 6    Pan et al.
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Growth property changes in response to NHERF1 
knockdown
One way to determine whether NHERF1 functions as a tumour
suppressor gene in human breast cancer is to assess the
resultant phenotypic responses by knocking down endog-
enous NHERF1 expression in NHERF1-high expressors. We
used a retrovirus-based system to deliver shRNA to knock
down NHERF1 expression in T47D cells. Introduction of
NHERF1 shRNA-786 markedly lowered the NHERF1 level
(Figure 1b, left panel). By contrast, NHERF1 expression was
unaffected by empty retrovirus (Babe). ShRNA can sometimes
create non-specific outcomes that are not related to the tar-
geted gene of interest [33]. To ascertain the specificity of phe-
notypic changes resulting from NHERF1 loss, we also
prepared an NHERF1 knockdown line from MCF7 cells by
introducing a different targeting sequence, NHERF1 shRNA-
910. Introducing shRNA-910 led to virtual elimination of
NHERF1 expression in MCF7 cells, in comparison with that of
parental cells and Babe control (Figure 1b, right panel).
One frequent response of a given tumour suppressor gene is
to inhibit cell proliferation. To determine whether NHERF1
affects cell proliferation, we sought to compare the growth
curve of T47D/NHERF-786 and MCF7/NHERF-910 cells with
that of their corresponding Babe controls, as determined by
MTT assay in 96-well plates. As shown in Figure 2a and 2b,
although infection of Babe retrovirus did not affect cell prolif-
eration (parental T47D versus T47D/Babe cells), T47D/
NHERF-786 cells grew consistently faster than T47D/Babe
control cells, most obviously at days 6 and 7 after plating (by
approximately 35%). Similarly, the growth rate of MCF7/
NHERF-910 was found to be higher (by 30% to 40%) than
that of MCF7/Babe or parental MCF7 cells (Figure 2c). These
results suggested an inhibitory effect of NHERF1 on cell pro-
liferation.
The DNA synthesis of these cells was also compared using
[3H]-thymidine incorporation assays. Knockdown of NHERF1
in T47D cells resulted in a significantly higher DNA synthesis
rate than that of the Babe control cells (P = 0.022; Figure 3a).
Figure 1
Knockdown of Na+/H+ exchanger regulatory factor 1 (NHERF1) expression in breast cancer cells Knockdown of Na+/H+ exchanger regulatory factor 1 (NHERF1) expression in breast cancer cells. (a) Breast cancer cell lines, as indicated, were 
analysed for NHERF1 expression by immunoblotting. Blots were stripped and re-probed with β-actin for loading control. (b) Short hairpin RNA 
(shRNA) sequences targeting two different positions of human NHERF1 mRNA, NHERF-786 and NHERF-910, were retrovirally transduced in T47D 
and MCF7 cells, as shown. Cells were also infected with empty virus (Babe) to be used as a control. Cells that expressed NHERF1 shRNA 
sequences were selected by 0.5 μg/ml of puromycin. NHERF1 expression in MCF7 and T47D stable cells and their parental lines was examined by 
immunoblotting. α-Tubulin blotting was used for normalisation.Available online http://breast-cancer-research.com/content/8/6/R63
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MCF7 cells with NHERF1 knockdown consistently showed
accelerated proliferation (P = 4 × 10-6; Figure 3b). The regu-
latory effect of NHERF1 on cell proliferation was also reflected
in anchorage-independent growth. T47D/NHERF-786 cells
showed a more efficient colony outgrowth in soft agar than did
either parental T47D (P = 0.0043) or T47D/Babe (P = 0.020)
cells (Figure 3c), indicating that NHERF1 exhibits growth sup-
pression activity in breast cancer cells.
Tumour growth properties in vivo
The growth-promotion response as result of NHERF1 knock-
down was also examined in a mouse xenograft model. We
compared the in vivo growth of T47D cells infected with
NHERF1 shRNA-786 retrovirus or vector control. To facilitate
tumour formation from T47D cells, which are oestrogen-
dependent, we pre-implanted each mouse subcutaneously
with a slow-release oestrogen pellet. Two days after pellet
implantation, T47D/NHERF-786 or T47D/Babe cells were
mixed with Matrigel and injected into the mouse mammary
pads. Tumours were visibly established in mice 42 days after
injection, when all mice were sacrificed to compare tumour
size. As shown in Figure 4a and 4b, tumours formed from
T47D/NHERF-786 (72.4 ± 13.9 mg, n = 10) were signifi-
cantly larger than those from T47D/Babe cells (37.7 ± 8.8 mg,
n = 8) (P = 0.043), suggesting that lowered NHERF1 expres-
sion promotes tumour growth in vivo. None of the tumours
was found to metastasise to lung or liver.
Effect of NHERF1 on cell cycle progression
To examine whether the growth-inhibitory activity of NHERF1
can be attributed to its effect on cell cycle progression, we first
compared the cell cycle distribution of asynchronised
Figure 2
Growth of T47D and MCF7 cells with Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown Growth of T47D and MCF7 cells with Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown. (a) Representative phase-contrast view of mon-
olayer culture of T47D/NHERF-786 cells in comparison with T47D/Babe control, prior to MTT assay. (b) Growth-rate comparison of T47D/NHERF-
786 and T47D/Babe cells by MTT assay. Cells cultured in 96-well plates were allowed to grow for 1 to 7 days before MTT reagents were added. 
The metabolic products of MTT deposited in cells were measured by optical density (O.D.) at 570 nm. (c) MCF7/NHERF-910 and MCF7/Babe cells 
were measured by MTT assay as described in (b). The growth curve is representative of at least three independent experiments. *P < 0.05 versus 
Babe cells. #P < 0.05 versus parental cells. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.Breast Cancer Research    Vol 8 No 6    Pan et al.
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NHERF1-negative and -positive T47D and MCF7 cells. As
shown in Figure 5a, T47D/NHERF-786 cells had a lower G1/
G0 and a higher S-phase population (G1/G0 50.4% ± 0.69%,
S 33.3% ± 0.95%) than Babe control cells (G1/G0 58.6% ±
1.49%, S 26.0% ± 1.03%). No significant difference was
observed in G2/M-phase populations between the two groups
(16.3% ± 0.64% versus 15.4% ± 0.47%). Similar results
were shown for MCF7 cells with NHERF1 knockdown (G1/G0
37.2% ± 1.69%, S 42.1% ± 0.98%, and G2/M 20.4% ±
0.60% for NHERF-910 versus G1/G0 43.9% ± 1.75%, S
33.8% ± 1.39%, and G2/M 22.3% ± 0.39% for Babe; Figure
5b), which suggested that NHERF1 affects cell cycle progres-
sion, probably by stalling cells at G1 phase.
To analyse this possibility in more detail, we serum-starved
MCF7 cells to arrest the cell cycle at the G1/G0 phase. One
day of starvation led to accumulation of G1 phase from approx-
imately 40% with normal serum condition to more than 70%
with serum starvation. The cells were then re-fed with medium
containing 10% serum and were allowed to grow for 0 to 29
hours before being harvested for FACS analyses (Figure 6a).
At 14 hours after serum feeding, G1/G0 phase cells began
advancing to the S phase. Between 14 and 19 hours, a
remarkable increase occurred in the S-phase population.
Comparing MCF7/Babe and MCF7/NHERF-910 cells, we
found that NHERF-910 cells proceeded to S phase signifi-
cantly faster than their corresponding control. At the 19-hour
point, 43.2% and 50.0% of the Babe and NHERF-910 cells,
respectively, were in S phase. This trend lasted through 24
hours after serum feeding. At 24 hours, S phase comprised
53.9% and 60.3% of the Babe and NHERF-910 cells, respec-
tively (Figure 6a). In contrast, more cells remained at G1 phase
in the Babe (47.8% and 30.8%) than in the NHERF-910
group (42.4% and 23.2%) at the 19- and 24-hour time points,
respectively. These results indicated that NHERF1 prohibited
G1-to-S cell cycle transition, reflecting the growth-inhibitory
activity of NHERF1.
Phosphorylation of Rb protein is one of the most critical proc-
esses in enforcing the G1-to-S transition [34]. To further verify
whether NHERF1 plays an inhibitory role in G1-to-S cell cycle
progression, we compared the Rb protein expression in
MCF7/Babe and MCF7/NHERF-910 cells. As shown in Fig-
ure 6b, the Rb protein in growth-arrested cells (at 0 hours) was
Figure 3
Lowered Na+/H+ exchanger regulatory factor 1 (NHERF1) expression leads to increased proliferation in an anchorage-dependent and -independent  manner Lowered Na+/H+ exchanger regulatory factor 1 (NHERF1) expression leads to increased proliferation in an anchorage-dependent and -independent 
manner. (a,b) NHERF1 knockdown T47D (a) and MCF7 (b) cells were pulsed with [3H]-thymidine to assay for DNA incorporation. Data are pre-
sented as means ± standard error, arbitrarily setting Babe at 100%. The average of three independent experiments was plotted. *P < 0.05, ***P < 
0.001. (c) Soft-agar assay. Parental T47D, Babe control, and NHERF-786 knockdown cells (1 × 104) were suspended in 1 ml of 1× culture medium 
that contained 0.35% agarose. The suspension was added on top of 4 ml of solidified 0.7% agarose. Plated cells were incubated for 20 days at 
37°C. Formed colonies larger than 50 μm in diameter were counted. Assays were performed in triplicate. The average of three independent experi-
ments is presented. *P < 0.05, **P < 0.01, in comparison with T47D/NHERF-786.Available online http://breast-cancer-research.com/content/8/6/R63
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mainly the hypo-phosphorylated form. Corresponding to the
beginning of S-phase entry at 14 hours after serum feeding,
we detected a high level of hyper-phosphorylated Rb, which
gradually receded during the observation period. In conso-
nance with an accelerated G1-to-S transition as a result of
NHERF1 loss, MCF7/NHERF-910 cells contained a signifi-
cantly higher level of hyper-phosphorylated Rb than did the
Babe control, most prominently at 14 hours and 19 hours after
serum feeding. To explore the mechanism responsible for the
difference in Rb phosphorylation and G1-to-S transition, we
compared the two groups of cells in their expression of some
of the most prominent cell cycle regulatory proteins (Figure
6b). No difference was shown in the level of p27, cdk2, cdk4,
or cyclin D1 between the MCF7/NHERF-910 and MCF7/
Babe cells. However, we found that the cyclin E level in MCF7/
NHERF-910 cells was significantly higher than that in MCF7/
Babe at 14 hours and 19 hours after serum stimulation (Figure
6b). A similar result was obtained from another independent
experiment. Taken together, these results indicated that
NHERF1 knockdown leads to accelerated G1-to-S transition
that may involve increased cyclin E content and elevated Rb
phosphorylation status.
Discussion
In the present study, we examined phenotypic changes in
response to knockdown of endogenous NHERF1 expression
by RNA interference. We found that the knockdown of
NHERF1 in human breast cancer cells led to enhanced growth
in either an anchorage-dependent or -independent manner.
Our study was conducted on a tissue type most relevant to
NHERF1 tumour suppressor activity. Results were verified in
two breast cancer cell lines and by using two different shRNA
targeting sequences. Coupled with our genetic evidence
reported earlier, the current functional analyses substantiate
NHERF1 as a tumour suppressor gene in mammary gland.
Figure 4
Tumour growth after injection into nude mice Tumour growth after injection into nude mice. Athymic nude mice were 
pre-implanted subcutaneously with oestrogen pellets to support tumour 
establishment. Three tenths of a million T47D/Babe (n = 10) or T47D/
NHERF-786 (n = 8) cells were injected into both sides of the mammary 
fat pads of each nude mouse (1.5 × 106 on each side). Forty-two days 
after injection, tumours were dissected (a) and weighed for growth 
comparison (b). Data are presented as means ± standard error. *P < 
0.05.
Figure 5
Effect of Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown  on cell cycle distribution Effect of Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown 
on cell cycle distribution. (a) The cell cycle distribution of asynchronous 
T47D cells (NHERF1 knockdown and Babe control) was determined 
by fluorescence-activated cell sorting (FACS) analyses. Cells were cul-
tured in media supplemented in 10% foetal bovine serum before being 
trypsinised, fixed in 75% ethanol, and stained with propidium iodide. 
(b) Cell cycle distribution of MCF7/NHERF-910 and MCF7/Babe cells 
was assessed by FACS. Three independent experiments were con-
ducted. Data are presented as means ± standard error. *P < 0.05, **P 
< 0.01, as compared with Babe cells.Breast Cancer Research    Vol 8 No 6    Pan et al.
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Phosphorylation of NHERF1 was shown to oscillate during
cell cycle progression [35]. However, it was not clear whether
NHERF1 plays a role in cell cycle regulation or how phospho-
modification on NHERF1 affects cell cycle transition. The cur-
rent study provides the first direct evidence indicating that the
normal NHERF1 function may involve deceleration of the G1-
to-S progression. The accelerated G1-to-S progression as a
result of NHERF1 knockdown is accompanied by elevated Rb
phosphorylation and cyclin E expression (Figure 6). Phospho-
rylation of Rb is believed to be triggered initially by cyclin D-
dependent kinase and then accelerated by cyclin E-cdk2 com-
plex [36,37]. An increase in cyclin E level as a result of
NHERF1 loss may speed up the process of Rb phosphoryla-
tion and subsequent E2F-mediated gene transcription for S-
phase entry. It is not clear at present how decreased NHERF1
expression enhances the cyclin E level. Given the contributing
role of cyclin E in mammary gland hyperplasia and tumourigen-
esis [38,39], it is conceivable that the deregulation of cyclin E
as a result of NHERF1 loss contributes to the breast cancer
initiation or progression.
Human  NHERF1  is thought to be an oestrogen-inducible
gene; NHERF1 mRNA and protein were found to be inducible
by oestrogen treatment, a response that is blocked by anti-
oestrogen [24]. A few half-sites of oestrogen response ele-
ment (ERE) at the 5'-regulatory sequences of the human
NHERF1 gene were found to be responsible for its oestrogen-
inducible expression [25]. In light of the key role of oestrogen
in mammary gland development and mitogenic responses of
many ER-α-positive breast cancer cells to oestrogen, it seems
paradoxical that NHERF1 would act as a tumour suppressor
gene in breast [22]. Our present study did not directly address
the relation of NHERF1 to oestrogen. However, when we com-
pared the NHERF1 shRNA and Babe cells (both T47D and
Figure 6
Stimulation of G1-to-S progression by Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown Stimulation of G1-to-S progression by Na+/H+ exchanger regulatory factor 1 (NHERF1) knockdown. (a) MCF7/NHERF-910 and MCF7/Babe cells 
were cultured in serum-free media for 1 day to accumulate cells at G1/G0 phase. Cells were then re-fed with medium supplemented with 10% foetal 
bovine serum for 0, 14, 19, 24, and 29 hours, when cells were trypsinised for fluorescence-activated cell sorting analyses of cell cycle progression. 
(b) Cells harvested at various time points were lysed for immunoblotting analyses of Rb, p27, cdk2, cdk4, cyclin D1, and cyclin E expression. Hyper-
phosphorylated and hypo-phosphorylated forms of Rb are indicated by arrow and arrowhead, respectively. Membranes were also probed with 
NHERF1 for knockdown verification and with β-actin for loading control. The result presented was representative of two independent experiments.Available online http://breast-cancer-research.com/content/8/6/R63
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MCF7), we found that NHERF1 expression status had no sig-
nificant effect on oestrogenic responses measured by DNA
synthesis and activation of ERE-driven reporter (our unpub-
lished data), suggesting that NHERF1 is at least not an imme-
diate mediator of classic oestrogen responses. Whether
NHERF1 precipitates certain oestrogenic effects other than
the canonical mitogenic responses remains to be determined.
It should be pointed out that NHERF1 expression in breast
cancer cells is not necessarily correlated with ER-α status. In
agreement with observations of primary breast carcinoma
[32], our panel of breast cancer cell lines revealed an incon-
sistent relationship between NHERF1 and ER-α positivity (Fig-
ure 1), suggesting that regulation of NHERF1 expression
exists at levels other than oestrogen stimulation. Speculatively,
alterations of these factors in mammary gland may cause an
imbalance of NHERF1 level that could lead to neoplasia. Inter-
estingly, the mouse NHERF1 gene does not contain the ERE
sites found in human NHERF1, and as a result, mouse
NHERF1 expression did not respond to oestrogen [40], sug-
gesting a difference in transcriptional regulation among spe-
cies to control NHERF1 expression.
The study presented here recapitulated the putative tumour
suppressor activity of NHERF1 in a cell culture model. A true
test of the NHERF1 effect on mammary tumourigenesis, how-
ever, would be to analyse mammary gland development and
susceptibility of mammary carcinogenesis in NHERF1 knock-
out mice [41]. Recently, we found that NHERF1-/- mice dis-
played elevated ductal side branching and extensive mammary
gland hyperplasia (our unpublished data). This observation is
consistent with the data of this study, which indicate that
NHERF1 suppresses cell growth at the mammary site.
Whether the disturbance of mammary gland development as a
result of NHERF1 gene loss is sufficient to increase breast
cancer incidence needs to be investigated.
Although our study addressed the biologic effect of NHERF1
on the proliferation of breast cancer cells, it remains unclear
which NHERF1-associated pathway, among all NHERF1-
interacting partners, is responsible for the NHERF1 tumour
suppressor function. We reported earlier that NHERF1 inter-
acted with SYK and merlin [1]. The tumourigenic mutations of
NHERF1 partially or completely disrupt the binding of SYK or
merlin, both of which are tumour suppressors [19,20,42,43],
suggesting that NHERF1 converges in a pathway mediated by
the two tumour suppressors. Recently, NHERF1 was reported
to interact with PDGFR and PTEN (phosphatase and tensin
homologue [mutated in multiple advanced cancers 1]), form-
ing a ternary complex [44]. NHERF1 was hypothesised to
assist in recruitment of PTEN to attenuate the PI3K (phosph-
oinositide-3 kinase) activity initiated by PDGF. Although the
hypothesis contrasts with the cooperative effect of NHERF1
on PDGF signaling as suggested by some earlier studies
[9,21], this mechanism is consistent with the tumour suppres-
sor activity presented in this study. Whether the negative reg-
ulation of growth factor signaling by NHERF1 is responsible
for the NHERF1 tumour suppressor function in mammary
gland remains to be determined.
Conclusion
By functional analyses, we show for the first time that NHERF1
possesses growth suppressor activity. We further show that
the G1-to-S cell cycle progression is accelerated by NHERF1
knockdown, a phenotype that is accompanied by increased
levels of cyclin E and phosphorylated Rb. Based on our pub-
lished genetic evidence implicating NHERF1 as a tumour sup-
pressor gene [1], we propose that one of the functional
activities responsible for its tumour suppressor role is prolifer-
ative suppression of mammary epithelial cells. Together, our
findings suggest that NHERF1 constitutes a proliferation con-
trol pathway in breast cells, justifying further studies of a novel
pathway that may represent a potential opportunity for thera-
peutic intervention.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YP participated in the experimental design and interpretation
of results, carried out experimental procedures, and drafted
the manuscript. LW participated in the experimental design.
JLD participated in the experimental design and interpretation
of results and assisted in writing and editing the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This work was supported by National Institutes of Health Grant 
CA100278. The authors want to thank Drs. Jinsong Liu and Shi Yang 
for sharing plasmid constructs, Dr. Stephan Ethier for providing cell 
lines, Ms. Lore Feldman for scientific editing, and Ms. Jin He for artwork.
References
1. Dai JL, Wang L, Sahin AA, Bromeling LD, Schutte M, Pan Y:
NHERF (Na+/H+ exchanger regulatory factor) gene mutations
in human breast cancer.  Oncogene 2004, 23:8681-8687.
2. Weinman EJ, Steplock D, Shenolikar S: CAMP-mediated inhibi-
tion of the renal brush border membrane Na+-H+ exchanger
requires a dissociable phosphoprotein cofactor.  J Clin Invest
1993, 92:1781-1786.
3. Yun CHC, Oh S, Zizak M, Steplock D, Tsao S, Tse C-M, Weinman
EJ, Donowitz M: cAMP-mediated inhibition of the epithelial
brush border Na+/H+ exchanger, NHE3, requires an associat-
edregulatoryprotein.  PNAS 1997, 94:3010-3015.
4. Wang S, Raab RW, Schatz PJ, Guggino WB, Li M: Peptide bind-
ing consensus of the NHERF-PDZ1 domain match the C-ter-
minal sequence of cystic fibrosis transmembrane
conductance regulator (CFTR).  FEBS Lett 1998, 427:103-108.
5. Raghuram V, Mak DD, Foskett JK: Regulation of cystic fibrosis
transmembrane conductance regulator single-channel gating
by bivalent PDZ-domain-mediated interaction.  PNAS 2001,
98:1300-1305.
6. Short DB, Trotter KW, Reczek D, Kreda SM, Bretscher A, Boucher
RC, Stutts MJ, Milgram SL: An apical PDZ protein anchors the
cystic fibrosis transmembrane conductance regulator to the
cytoskeleton.  J Biol Chem 1998, 273:19797-19801.
7. Hall RA, Premont RT, Chow CW, Blitzer JT, Pitcher JA, Claing A,
Stoffel RH, Barak LS, Shenolikar S, Weinman EJ, et al.: The beta2-
adrenergic receptor interacts with the Na+/H+-exchanger reg-Breast Cancer Research    Vol 8 No 6    Pan et al.
Page 10 of 10
(page number not for citation purposes)
ulatory factor to control Na+/H+  exchange.  Nature 1998,
392:626-630.
8. Cao TT, Deacon HW, Reczek D, Bretscher A, von Zastrow M: A
kinase-regulated PDZ-domain interaction controls endocytic
sorting of the beta2-adrenergic receptor.  Nature 1999,
401:286-290.
9. Maudsley S, Zamah AM, Rahman N, Blitzer JT, Luttrell LM, Lefkow-
itz RJ, Hall RA: Platelet-derived growth factor receptor associ-
ation with Na+/H+ exchanger regulatory factor potentiates
receptor activity.  Mol Cell Biol 2000, 20:8352-8363.
10. James MF, Beauchamp RL, Manchanda N, Kazlauskas A, Ramesh
V: A NHERF binding site links the betaPDGFR to the cytoskel-
eton and regulates cell spreading and migration.  J Cell Sci
2004, 117:2951-2961.
11. Bernardo AA, Kear FT, Santos AVP, Ma J, Steplock D, Robey RB,
Weinman EJ: Basolateral Na+/HCO3- cotransport activity is
regulated by the dissociable Na+/H+ exchanger regulatory fac-
tor.  J Clin Invest 1999, 104:195-201.
12. Tang Y, Tang J, Chen Z, Trost C, Flockerzi V, Li M, Ramesh V, Zhu
MX: Association of mammalian Trp4 and phospholipase C iso-
zymes with a PDZ domain-containing protein, NHERF.  J Biol
Chem 2000, 275:37559-37564.
13. Hwang JI, Heo K, Shin KJ, Kim E, Yun C, Ryu SH, Shin HS, Suh
PG: Regulation of phospholipase C-beta 3 activity by Na+/H+
exchanger regulatory factor 2.  J Biol Chem 2000,
275:16632-16637.
14. Hall RA, Spurney RF, Premont RT, Rahman N, Blitzer JT, Pitcher
JA, Lefkowitz RJ: G protein-coupled receptor kinase 6A phos-
phorylates the Na+/H+ exchanger regulatory factor via a PDZ
domain-mediated interaction.  J Biol Chem 1999,
274:24328-24334.
15. Mohler PJ, Kreda SM, Boucher RC, Sudol M, Stutts MJ, Milgram
SL: Yes-associated protein 65 localizes p62c-Yes to the apical
compartment of airway epithelia by association with EBP50.  J
Cell Biol 1999, 147:879-890.
16. Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S: EBP50,
a beta-catenin-associating protein, enhances Wnt signaling
and is over-expressed in hepatocellular carcinoma.  Hepatol-
ogy 2003, 38:178-186.
17. Murthy A, Gonzalez-Agosti C, Cordero E, Pinney D, Candia C,
Solomon F, Gusella J, Ramesh V: NHERF, a regulatory cofactor
for Na+-H+ exchanger, is a common interactor for merlin and
ERM (MERM) proteins.  J Biol Chem 1998, 273:1273-1276.
18. Reczek D, Berryman M, Bretscher A: Identification of EBP50: a
PDZ-containing phosphoprotein that associates with mem-
bers of the ezrin-radixin-moesin family.  J Cell Biol 1997,
139:169-179.
19. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Mari-
neau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, et
al.: Alteration in a new gene encoding a putative membrane-
organizing protein causes neuro-fibromatosis type 2.  Nature
1993, 363:515-521.
20. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry
DM, Eldridge R, Kley N, Menon AG, Pulaski K, et al.: A novel
moesin-, ezrin-, radixin-like gene is a candidate for the neurofi-
bromatosis 2 tumor suppressor.  Cell 1993, 72:791-800.
21. Demoulin JB, Seo JK, Ekman S, Grapengiesser E, Hellman U,
Ronnstrand L, Heldin CH: Ligand-induced recruitment of Na+/
H+-exchanger regulatory factor to the PDGF (platelet-derived
growth factor) receptor regulates actin cytoskeleton reorgani-
zation by PDGF.  Biochem J 2003, 376:505-510.
22. Voltz JW, Weinman EJ, Shenolikar S: Expanding the role of
NHERF, a PDZ-domain containing protein adaptor, to growth
regulation.  Oncogene 2001, 20:6309-6314.
23. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Macher
ER: Somatic NF2 gene mutations in familial and non-familial
vestibular schwannoma.  Hum Mol Genet 1994, 3:347-350.
24. Ediger TR, Kraus WL, Weinman EJ, Katzenellenbogen BS: Estro-
gen receptor regulation of the Na+/H+ exchanger regulatory
factor.  Endocrinology 1999, 140:2976-2982.
25. Ediger TR, Park S-E, Katzenellenbogen BS: Estrogen receptor
inducibility of the human Na+/H+ exchanger regulatory factor/
ezrin-radixin-moesin binding protein 50 (NHE-RF/EBP50)
gene involving multiple half-estrogen response elements.  Mol
Endocrinol 2002, 16:1828-1839.
26. Wang L, Pan Y, Dai JL: Evidence of prooncogenic activity of
MKK4 in breast and pancreatic tumors.  Oncogene 2004,
23:5978-5985.
27. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J: Inhibition
of breast and ovarian tumor growth through multiple signaling
pathways by using retrovirus-mediated small interfering RNA
against Her-2/neu gene expression.  J Biol Chem 2004,
279:4339-4345.
28. Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin
A, Mendez R, Dai JL: Alternative splicing disrupts a nuclear
localization signal in spleen tyrosine kinase that is required for
invasion suppression in breast cancer.  Cancer Res 2003,
63:4724-4730.
29. Ellison G, Klinowska T, Westwood RFR, Docter E, French T, Fox
JC:  Further evidence to support the melanocytic origin of
MDA-MB-435.  Mol Pathol 2002, 55:294-299.
30. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer
V, Jeffrey SS, Van de Rijn M, Waltham M, et al.: Systematic vari-
ation in gene expression patterns in human cancer cell lines.
Nat Genet 2000, 24:227-235.
31. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D:
Lineage infidelity of MDA-MB-435 cells: expression of melano-
cyte proteins in a breast cancer cell line.  Cancer Res 2004,
64:3479-3485.
32. Stemmer-Rachamimov AO, Wiederhold T, Nielsen GP, James M,
Pinney-Michalowski D, Roy JE, Cohen WA, Ramesh V, Louis DN:
NHERF, a merlin-interacting protein, is primarily expressed in
luminal epithelia, proliferative endometrium, and estrogen
receptor-positive breast carcinomas.  Am J Pathol 2001,
158:57-62.
33. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG,
Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee
A, Meyerson M, et al.: Short interfering RNAs can induce unex-
pected and divergent changes in the levels of untargeted pro-
teins in mammalian cells.  PNAS 2004, 101:1892-1897.
34. Sherr CJ: Cancer cell cycles.  Science 1996, 274:1672-1677.
35. He J, Lau AG, Yaffe MB, Hall RA: Phosphorylation and cell cycle-
dependent regulation of Na+/H+ exchanger regulatory factor-
1 by Cdc2 kinase.  J Biol Chem 2001, 276:41559-41565.
36. Mittnacht S, Lees JA, Desai D, Harlow E, Morgan DO, Weinberg
RA:  Distinct sub-populations of the retinoblastoma protein
show a distinct pattern of phosphorylation.  EMBO J 1994,
13:118-127.
37. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA:
Regulation of retinoblastoma protein functions by ectopic
expression of human cyclins.  Cell 1992, 70:993-1006.
38. Bortner DM, Rosenberg MP: Induction of mammary gland
hyperplasia and carcinomas in transgenic mice expressing
human cyclin E.  Mol Cell Biol 1997, 17:453-459.
39. Hunt KK, Keyomarsi K: Cyclin E as a prognostic and predictive
marker in breast cancer.  Semin Cancer Biol 2005, 15:319-326.
40. Weinman EJ, Steplock D, Zhang X, Akhter S, Shenolikar S: Molec-
ular cloning of the cDNA and promoter sequences for the
mouse sodium-hydrogen exchanger regulatory factor.  Bio-
chem Biophys Acta 1999, 1447:71-76.
41. Shenolikar S, Voltz JW, Minkoff CM, Wade JB, Weinman EJ: Tar-
geted disruption of the mouse NHERF-1 gene promotes inter-
nalization of proximal tubule sodium-phosphate cotransporter
type IIa and renal phosphate wasting.  PNAS 2002,
99:11470-11475.
42. Coopman PJ, Do MTH, Barth M, Bowden ET, Hayes AJ, Basyuk E,
Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, et al.: The
Syk tyrosine kinase suppresses malignant growth of human
breast cancer cells.  Nature 2000, 406:742-747.
43. Yuan YF, Mendez R, Sahin A, Dai JL: Hypermethylation leads to
silencing of the SYK gene in human breast cancer.  Cancer Res
2001, 61:5558-5561.
44. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM: PTEN
tumor suppressor associates with NHERF proteins to attenu-
ate PDGF receptor signaling.  EMBO J 2006, 25:910-920.